These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

395 related articles for article (PubMed ID: 32973794)

  • 1. To Remember or to Forget: The Role of Good and Bad Memories in Adoptive T Cell Therapy for Tumors.
    Mondino A; Manzo T
    Front Immunol; 2020; 11():1915. PubMed ID: 32973794
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of memory T cell subsets for adoptive immunotherapy.
    Busch DH; Fräßle SP; Sommermeyer D; Buchholz VR; Riddell SR
    Semin Immunol; 2016 Feb; 28(1):28-34. PubMed ID: 26976826
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tissue-resident memory-like T cells in tumor immunity: Clinical implications.
    Dhodapkar MV; Dhodapkar KM
    Semin Immunol; 2020 Jun; 49():101415. PubMed ID: 33011063
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor-derived ILT4 induces T cell senescence and suppresses tumor immunity.
    Gao A; Liu X; Lin W; Wang J; Wang S; Si F; Huang L; Zhao Y; Sun Y; Peng G
    J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33653799
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tissue-resident memory CD8
    Wang T; Shen Y; Luyten S; Yang Y; Jiang X
    Pharmacol Res; 2020 Sep; 159():104876. PubMed ID: 32422340
    [TBL] [Abstract][Full Text] [Related]  

  • 6. γδ T cells in cancer immunotherapy.
    Zou C; Zhao P; Xiao Z; Han X; Fu F; Fu L
    Oncotarget; 2017 Jan; 8(5):8900-8909. PubMed ID: 27823972
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differentiation and Regulation of T
    Basu A; Ramamoorthi G; Albert G; Gallen C; Beyer A; Snyder C; Koski G; Disis ML; Czerniecki BJ; Kodumudi K
    Front Immunol; 2021; 12():669474. PubMed ID: 34012451
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The use of endogenous T cells for adoptive transfer.
    Yee C
    Immunol Rev; 2014 Jan; 257(1):250-63. PubMed ID: 24329802
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Understanding T cell phenotype for the design of effective chimeric antigen receptor T cell therapies.
    Tantalo DG; Oliver AJ; von Scheidt B; Harrison AJ; Mueller SN; Kershaw MH; Slaney CY
    J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34035114
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Potential of Tissue-Resident Memory T Cells for Adoptive Immunotherapy against Cancer.
    Beumer-Chuwonpad A; Taggenbrock RLRE; Ngo TA; van Gisbergen KPJM
    Cells; 2021 Aug; 10(9):. PubMed ID: 34571883
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adoptive cellular therapy of cancer: exploring innate and adaptive cellular crosstalk to improve anti-tumor efficacy.
    Payne KK; Bear HD; Manjili MH
    Future Oncol; 2014 Aug; 10(10):1779-94. PubMed ID: 25303057
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CD8
    Farhood B; Najafi M; Mortezaee K
    J Cell Physiol; 2019 Jun; 234(6):8509-8521. PubMed ID: 30520029
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prospects for chimeric antigen receptor (CAR) γδ T cells: A potential game changer for adoptive T cell cancer immunotherapy.
    Mirzaei HR; Mirzaei H; Lee SY; Hadjati J; Till BG
    Cancer Lett; 2016 Oct; 380(2):413-423. PubMed ID: 27392648
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chimeric antigen receptor engineered NK cellular immunotherapy overcomes the selection of T-cell escape variant cancer cells.
    Lee MY; Robbins Y; Sievers C; Friedman J; Abdul Sater H; Clavijo PE; Judd N; Tsong E; Silvin C; Soon-Shiong P; Padget MR; Schlom J; Hodge J; Hinrichs C; Allen C
    J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33741731
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CAR-T Cells Hit the Tumor Microenvironment: Strategies to Overcome Tumor Escape.
    Rodriguez-Garcia A; Palazon A; Noguera-Ortega E; Powell DJ; Guedan S
    Front Immunol; 2020; 11():1109. PubMed ID: 32625204
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Principles of adoptive T cell therapy in cancer.
    Met Ö; Jensen KM; Chamberlain CA; Donia M; Svane IM
    Semin Immunopathol; 2019 Jan; 41(1):49-58. PubMed ID: 30187086
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bifunctional iRGD-anti-CD3 enhances antitumor potency of T cells by facilitating tumor infiltration and T-cell activation.
    Zhou S; Meng F; Du S; Qian H; Ding N; Sha H; Zhu M; Yu X; Wang L; Liu B; Wei J
    J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33986122
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cell Therapy With TILs: Training and Taming T Cells to Fight Cancer.
    Kumar A; Watkins R; Vilgelm AE
    Front Immunol; 2021; 12():690499. PubMed ID: 34140957
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Editorial: Tissue Resident Memory T Cells.
    Mami-Chouaib F; Tartour E
    Front Immunol; 2019; 10():1018. PubMed ID: 31191515
    [No Abstract]   [Full Text] [Related]  

  • 20. Adoptive transfer of ex vivo-activated memory T-cell subsets with cyclophosphamide provides effective tumor-specific chemoimmunotherapy of advanced metastatic murine melanoma and carcinoma.
    Gold JE; Zachary DT; Osband ME
    Int J Cancer; 1995 May; 61(4):580-6. PubMed ID: 7759164
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.